The Michael J. Fox Foundation (MJFF) announces 45 grants that total more than $69.1 million awarded in June and July 2024. review some of the supported projects aiming to improve how Parkinson’s disease (PD) is detected and monitored, develop drugs that slow or stop its progression and treat the symptoms that reduce mobility and increase the risk of falls. Read more: https://bit.ly/46Zf6Nt
The Michael J. Fox Foundation for Parkinson's Research
Research Services
New York, NY 41,295 followers
Here. Until Parkinson's isn't.
About us
The Michael J. Fox Foundation for Parkinson's Research is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today.
- Website
-
http://www.michaeljfox.org
External link for The Michael J. Fox Foundation for Parkinson's Research
- Industry
- Research Services
- Company size
- 51-200 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 2000
Locations
-
Primary
Grand Central Station
P.O. Box 4777
New York, NY 10163-4777, US
Employees at The Michael J. Fox Foundation for Parkinson's Research
-
Cynthia Ramnarace
Editorial Content Strategy
-
Susan Otten, MBA, ABC
Logistics, marketing, leadership. Logistics for CPG & shelf-stable food companies who do good. Appalachian Trail Thru-Hiker for Parkinson's Disease…
-
Kevin Murray
Fundraiser, Trial Participant, Motorsports Enthusiast
-
Ted Thompson
Senior VP @ MJFF | Leading Parkinson's Public Policy
Updates
-
Thank you to Koneksa for sponsoring this year’s Parkinson’s Disease Therapeutics conference. Koneska stands at the forefront of digital biomarker evolution to develop robust, validated and patented algorithms designed to support early detection and specific therapeutics considerations for Parkinson’s disease research. The PD Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. Our 16th annual conference will be happening on October 17th in New York City. Visit our website to learn more. https://bit.ly/3XaQq1c
2024 Parkinson's Disease Therapeutics Conference
michaeljfox.org
-
Though existing evidence supports that dysfunction in the clearing of cellular debris plays an important role in the development of Parkinson's disease, many unanswered questions remain regarding the mechanisms of the autophagy-lysosomal pathway involved in this process. In the newest episode of the Parkinson’s Research Podcast, Dr. Zhenyu Yue, Aidekman Research Professor in the Department of Neurology and The Friedman Brain Institute, discusses his research investigating the cellular and molecular mechanisms for Parkinson’s disease and other neurodegenerative diseases. Listen to the episode: https://bit.ly/3WXLbR3 *This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at michaeljfox.org/podcasts.
Episode 21: The Autophagy-Lysosomal Pathway and Development of Relevant PD Biomarkers with Zhenyu Yue
michaeljfox.org
-
Finding the right Parkinson’s treatment plan can be a trial-and-error process. The kind of medication, the dosage, the timing, lifestyle factors and more are all important pieces of the puzzle. Medication management is a popular topic in the Parkinson’s community, with many seeking guidance as they navigate their journey with treatment. In August’s highly attended webinar, Jimmy Choi leads a discussion with Allison Signorelli, Eric Jackowiak, MD and Brian Fiske, PhD. They talk about different medication options, practical tips for finding what works best for you and the latest research on emerging treatments. Listen to our new podcast episode featuring audio from the webinar: https://bit.ly/46YpwwL
-
"Make-A-Will Month is all about reminding us that we have the power to secure our legacy and protect our loved ones through the act of creating a will. I work daily to support individuals in finding a way to give that reflects their values, protects their loved ones and ensures the causes they care about the most will be supported — like bringing us closer to a future without Parkinson’s." – Shirley N., Director of Planned Giving at MJFF. August is Make-A-Will Month, a national campaign dedicated to raising awareness about the importance of having a will. 67 percent of U.S. adults haven’t created a will, despite 64 percent believing it’s important. Having a will ensures your wishes are honored and provides peace of mind for you and your loved ones. In honor of Make-A-Will Month, we invite you to join our upcoming virtual talk to learn how to protect yourself and your family financially, as well as plan for future care costs and changes. Whether you are living with Parkinson’s, have a loved one with Parkinson’s, or simply want to secure your legacy, this talk is for you. Register now: https://bit.ly/3WYXixs
-
-
Research shows mindfulness and meditation can improve some Parkinson’s symptoms and help people live a better life with the disease, but it isn’t always easy to put into practice. In our new podcast episode, Rachel Dolhun, MD, DipABLM, principal medical advisor at MJFF, leads a discussion about how to incorporate mindfulness and meditation in your PD journey. Our expert panelists are: • Sree S.: San Francisco Bay area-based photographer and daily practitioner of mindfulness and meditation, diagnosed with PD in 2015. • Ken Hill: Semi-retired IT professional with a daily meditation and mindfulness practice. Ken's wife, Kat, was diagnosed with PD in 2015. • Sarah Mulukutla, MD, MPH: Integrative neurologist and founder of Mindful Neurology. Dr Mulukutla teaches mind-body strategies and is researching the effect they have on people with Parkinson’s. Tune into the episode for practical tips, advice and a guided meditation you can try at home: https://bit.ly/46Sy3Bc
-
Today, MJFF Board member Ryan Reynolds opens up on the cover of PEOPLE Magazine | PEOPLE.com and sheds light on his family’s journey with Parkinson’s disease. Ryan and his mother Tammy, part of the educational #MoretoParkinsons campaign, provide a candid conversation as loved ones caring for their father and husband James (Jim) Reynolds who lived with Parkinson’s disease and experienced hallucinations and delusions. Ryan shares, “At the time I just thought, ‘My dad’s losing his mind.’ My father was really slipping down a rabbit hole where he was struggling to differentiate between reality and fiction.” Not everyone with Parkinson’s disease experiences hallucinations or delusions. Like all Parkinson’s symptoms, if, when and to what degree they occur varies from person to person. But it’s normal and perfectly understandable to worry about the possibility of these symptoms. Learn more about what these symptoms can look like, how to talk about hallucinations and delusions with loved ones and doctors and what medication and non-medication strategies may help you and your care partners ease these symptoms. https://bit.ly/3X4LqLx
-
-
Deadline Approaching: Neurology residents are invited to join us in Chicago this fall for a free, expert-led course on research, care and careers in movement disorders. Apply by September 6th. bit.ly/4eixDav.
Two-Day Course on Movement Disorders
education.movementdisorders.org
-
Evidence supports that dysfunction in the homeostasis of iron and other elements likely contributes to the pathophysiological mechanisms of Parkinson's disease, but we have yet to develop suitable elemental biomarkers for use in diagnosing and monitoring the progression of Parkinson's disease. In the latest episode of the Parkinson’s Research Podcast, Dr. Paul Lingor, Professor of Neurology at the Technical University of Munich, discusses his work to identify patterns of bioelements in CSF that could serve as PD biomarkers. Beyond CSF, he is also examining tear fluid as a potential biomarker source that is easier to collect. Listen to the episode now: https://bit.ly/4dC1REl *This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://lnkd.in/eAp9HDGe.
Episode 20: Studying CSF Element Profiles and Tear Fluid as Potential Biomarkers, and Novel and Combined Therapies for PD with Paul Lingor
michaeljfox.org
-
The U.S. Food and Drug Administration (FDA) has approved a new, long-acting oral formulation for the treatment of Parkinson’s disease (PD). Developed by Amneal Pharmaceuticals, Crexont is an extended-release formulation of levodopa/carbidopa that aims to alleviate symptoms longer with fewer doses and offer patients improved symptom control and a better quality of life. Read more about this treatment and the bustling pipeline of PD drugs: https://bit.ly/3yxZKTm
-